Expertise in
8
conditions

Dr. Amita Patnaik

Oncology
Office
4383 Medical Dr Ste 3046, 
San Antonio, TX 
Clinical Trials:Currently Recruiting for 3 Trials
Accepting New Patients
Expertise in
8
conditions
Office
4383 Medical Dr Ste 3046, 
San Antonio, TX 

Overview

Amita Patnaik is an Oncologist practicing medicine in San Antonio, Texas.

Dr. Patnaik is highly rated in 8 conditions, according to our data. Her clinical expertise encompasses Adenoid Cystic Carcinoma, Melanoma, Breast Cancer, and Non-Small Cell Lung Cancer (NSCLC).

She is actively involved in clinical research, co-authoring 100 peer reviewed articles and participating in 24 clinical trials. Dr. Patnaik is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in TX

Hospital Affiliations

Methodist Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community First Health Plans
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

Office
4383 Medical Dr Ste 3046, San Antonio, TX 78229

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

24 Clinical Trials

A Phase 1 Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
A Phase 1 Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: July 22, 2026
Intervention Type: Drug
Study Drug: SGN-PDL1V
Study Phase: Phase 1
A Phase 1 Study of Sigvotatug Vedotin in Advanced Solid Tumors
A Phase 1 Study of Sigvotatug Vedotin in Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: July 06, 2026
Intervention Type: Drug
Study Drug: SGN-B6A
Study Phase: Phase 1
A Phase 1a/1b, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
A Phase 1a/1b, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: March 18, 2026
Intervention Type: Drug, Combination product
Study Phase: Phase 1
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Biological
Study Drug: Dostarlimab
Study Phase: Phase 1
A Phase 1/1b Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
A Phase 1/1b Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: July 15, 2026
Intervention Type: Drug
Study Drug: SRF388
Study Phase: Phase 1
A Phase 1 Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
A Phase 1 Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: January 09, 2026
Intervention Type: Drug
Study Drug: SGN-B7H4V
Study Phase: Phase 1
Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin
Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin
Enrollment Status: Terminated
Publish Date: June 11, 2025
Intervention Type: Drug
Study Drug: AVID100
Study Phase: Phase 1/Phase 2
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: February 07, 2025
Intervention Type: Drug
Study Drug: SGN-STNV
Study Phase: Phase 1
A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
Enrollment Status: Completed
Publish Date: February 04, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1a/1b Study of a Novel Anti-PD-L1 Checkpoint Antibody (LY3300054) Administered Alone or in Combination With Other Agents in Advanced Refractory Solid Tumors (Phase 1a/1b Anti-PD-L1 Combinations in Tumors-PACT)
A Phase 1a/1b Study of a Novel Anti-PD-L1 Checkpoint Antibody (LY3300054) Administered Alone or in Combination With Other Agents in Advanced Refractory Solid Tumors (Phase 1a/1b Anti-PD-L1 Combinations in Tumors-PACT)
Enrollment Status: Completed
Publish Date: September 27, 2024
Intervention Type: Drug
Study Phase: Phase 1
View 7 Less Clinical Trials

100 Total Publications

Author Correction: Casdatifan shows durable response linked to HIF-2α biology in kidney cancer.
Author Correction: Casdatifan shows durable response linked to HIF-2α biology in kidney cancer.
Journal: Nature
Published: August 05, 2026
Similar Doctors
Expertise in
17
conditions
Expertise in
17
conditions
Referral may be required

University Of Texas Health Science Center At San Antonio

7979 Wurzbach Rd, 
San Antonio, TX 
 (1.0 miles away)
210-450-1000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrew Brenner is an Oncologist practicing medicine in San Antonio, Texas. Dr. Brenner is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Astrocytoma, Glioblastoma, Glioma, Colonoscopy, and Endoscopy. Dr. Brenner is currently accepting new patients.

Expertise in
25
conditions
Expertise in
25
conditions
Referral may be required

University Of Texas Health Science Center At San Antonio

7979 Wurzbach Rd, 
San Antonio, TX 
 (1.0 miles away)
210-450-1143
Languages Spoken:
English, Mandarin
See accepted insurances
Accepting New Patients
Offers Telehealth

Lei Zheng is an Oncologist practicing medicine in San Antonio, Texas. Dr. Zheng is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Familial Pancreatic Cancer, Pancreaticoduodenectomy, and Hepato-Pancreato-Biliary Surgery. Dr. Zheng is currently accepting new patients.

Expertise in
18
conditions
Expertise in
18
conditions
Referral may be required

Texas Oncology - San Antonio Medical Center

5206 Research Dr, 
San Antonio, TX 
 (2.8 miles away)
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Antonio Santillan-Gomez is an Oncologist practicing medicine in San Antonio, Texas. Dr. Santillan-Gomez is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Ovarian Carcinosarcoma, Virilizing Ovarian Tumor, Cervical Cancer, Salpingo-Oophorectomy, and Hernia Surgery. Dr. Santillan-Gomez is currently accepting new patients.

Frequently Asked Questions about Dr. Amita Patnaik

How do I make an appointment with Dr. Amita Patnaik?

You can book an appointment with Dr. Amita Patnaik by calling their office at 210-593-5700. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Amita Patnaik a top-rated expert for Adenoid Cystic Carcinoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Amita Patnaik is classified as an Distinguished expert for Adenoid Cystic Carcinoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Amita Patnaik specialize in?

While Dr. Amita Patnaik is a Oncology, they have specific expertise in Adenoid Cystic Carcinoma, Melanoma, and Breast Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Amita Patnaik participate in research or clinical trials?

Yes. Dr. Amita Patnaik has published 100 articles and abstracts on conditions like Adenoid Cystic Carcinoma. You can view a list of Dr. Amita Patnaik's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Amita Patnaik accept my insurance?

Dr. Amita Patnaik accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 210-593-5700 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Patnaik's expertise for a condition
ConditionClose
    View All 23 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile